News

Population Pharmacokinetics (PopPK), a crucial approach in drug development

We are proud to be in the Top 500 of the Les Echos / Statista ranking of "Champions de la Croissance" in France.

We participated at the FDA workshop about the development of Best Practices in Physiologically Based Pharmacokinetic Modeling to Support Clinical Pharmacology Regulatory Decision-Making.

Development of a PBPK model of a molecule to be able to simulate the exposure in the synovial fluid and plasma following an intra-articular administration in adults.

PhinC Development would like to thank you for being part of this special event dedicated to the PBPK and organised jointly with Club Phase 1.

We are happy to announces the launch of our new subsidiary PhInc. Modeling in Montreal, Canada.

We celebrated, together with our colleagues from Drugs for Neglected Diseases initiative - DNDi and partners, the positive opinion given by the European Medicines Agency about Fexinidazole, DNDi’s first “new chemical entity”:

PhinC Development is proud to sponsor and participate in the special event organized by the GMP that will be held in Lyon on 16th to 18th October 2019.